# Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

> **NCT06796426** · — · AVAILABLE · sponsor: **Arrowhead Pharmaceuticals**

## Conditions studied

- Familial Chylomicronemia
- High Risk Severe Hypertriglyceridemia (SHTG)

## Interventions

- **DRUG:** Plozasiran

## Key facts

- **NCT ID:** NCT06796426
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06796426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06796426, "Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06796426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*